Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.30 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13890009 | 1.00 | ALDH1A1 (0.32) | ALDH1A1LMNATHRBHTR2ATP53 | |
| SCHEMBL13712950 | 0.94 | PKM (0.33) | ALDH1A1LMNATHRBTP53 | |
| SCHEMBL13712219 | 0.94 | HTR2A (0.32) | HTR2AGRIN1GRIN2BL3MBTL1GAA | |
| SCHEMBL4488210 | 0.94 | HTR2A (0.32) | HTR2AGRIN1GRIN2BL3MBTL1GAA | |
| SCHEMBL4484765 | 0.93 | NPC1 (0.34) | ALDH1A1LMNATHRBTP53 | |
| SCHEMBL4484808 | 0.93 | HTR2A (0.32) | HTR2AGRIN1GRIN2BL3MBTL1GAA | |
| SCHEMBL4491791 | 0.93 | HTR2A (0.32) | HTR2AGRIN1GRIN2BL3MBTL1GAA | |
| SCHEMBL4484393 | 0.92 | MAPT (0.32) | ALDH1A1HTR2AGRIN1GRIN2BL3MBTL1 | |
| SCHEMBL13712229 | 0.92 | MAPT (0.32) | ALDH1A1HTR2AGRIN1GRIN2BL3MBTL1 | |
| SCHEMBL4490126 | 0.91 | CCNE1 (0.31) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582626-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111798-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | ALDH1A1 417/4885LMNA 1248/4885THRB 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.